Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
NCT03936023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 182126
Last updated 2023-08-01
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Saxagliptin
Saxagliptin dispensing claim is the exposure
- DRUG
-
2nd generation sulfonylurea dispensing claim is used as the reference
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Womens
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Emulation of the SOUL Diabetes Trial in Healthcare Claims
NCT06659718 ·Status: COMPLETED
-
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims
NCT06659744 ·Status: COMPLETED
-
Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
NCT00661362 ·Status: COMPLETED ·Phase: PHASE3
-
Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin
NCT01006603 ·Status: COMPLETED ·Phase: PHASE4
-
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
NCT00960076 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
NCT00614939 ·Status: COMPLETED ·Phase: PHASE3
-
Saxagliptin and Cardiac Structure and Function
NCT02481479 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
NCT01006590 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
NCT00374907 ·Status: COMPLETED ·Phase: PHASE3
-
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
NCT00666458 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects
NCT00935467 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT03989232 ·Status: COMPLETED ·Phase: PHASE3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
NCT02551874 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes
NCT02307695 ·Status: UNKNOWN ·Phase: PHASE4
-
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
NCT01086293 ·Status: COMPLETED
-
Saxagliptin Triple Oral Therapy
NCT01128153 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
NCT02182895 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
NCT00683657 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
NCT02531035 ·Status: COMPLETED ·Phase: PHASE3
-
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
NCT03802487 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects
NCT03310944 ·Status: COMPLETED ·Phase: PHASE1
-
Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments
NCT01086280 ·Status: COMPLETED
-
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
NCT00918138 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
NCT03199053 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
NCT00885378 ·Status: COMPLETED ·Phase: PHASE3